Browse the latest reports in the Therapy Area industry below
-
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry more info
The PharmaSphere, Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013. GlobalData’s Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry’s attempts at moving toward an open R&D ecosystem.By: GlobalData, Published: Apr-2013, Product code: GDHC003PSR
PAGES:
85
TABLES:
27
FIGURES & CHARTS:
7
$2,995.00 -
EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022 more info
Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth of myeloid cells originating in the bone marrow that invade the blood and potentially other organs, depending on the phase of the cancer (ACS, 2012; NLM, 2012). Based on clinical characteristics and laboratory findings, CML is divided into three phases: chronic, accelerated, and blast crisis; most people with CML are diagnosed at the chronic phase (NLM, 2012). The diagnosis of CML is based on the presence of the Philadelphia (Ph) chromosome, which is the product of a distinctive cytogenetic abnormality where the BCR gene on chromosome 22 becomes fused to the ABL gene on chromosome 9, generating the BCR-ABL fusion oncogene, which produces the BCR-ABL protein and triggers CML. The Ph chromosome is present in 95% of CML patients (Jabbour and Kantarjian, 2012; Sawyers, 1999).By: GlobalData, Published: Apr-2013, Product code: GDHCER014
PAGES:
43
TABLES:
9
FIGURES & CHARTS:
7
$3,995.00 -
EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022 more info
Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults and is associated with a histologic and/or radiologic pattern of usual interstitial pneumonia (NHLBI, 2011; Raghu et al., 2011). As a fatal disease that falls under the umbrella of interstitial lung disease of unknown cause, IPF is limited to the lungs and manifests with irreversible and variable scarring, stiffening, and thickening of the lung tissues that leads to progressively worsening of pulmonary function (NHLBI, 2011; Raghu et al. 2011). IPF is the most common form of idiopathic interstitial pneumonia and also has the worst prognosis, with only three to five years of median survival (Olson and Swigris, 2012). Respiratory failure accounts for over 80% of IPF fatalities (Raghu et al., 2006). IPF is more common in men, and its prevalence typically increases with advancing age.By: GlobalData, Published: Apr-2013, Product code: GDHCER020
PAGES:
41
TABLES:
8
FIGURES & CHARTS:
6
$3,995.00 -
Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players more info
GBI Research, the leading business intelligence provider, has released its latest research, "Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players", which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pipeline.By: GBI Research, Published: Apr-2013, Product code: GBIHC285MR
PAGES:
88
TABLES:
72
FIGURES & CHARTS:
41
$3,500.00 -
EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022 more info
Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a multi-factorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. It results in symptoms of discomfort such as visual disturbance and tear film instability (DEWS, 2007). Middle-aged and older adults are the most commonly affected group because of the high prevalence of contact lens usage, systemic drug effects, autoimmune diseases, and refractive surgeries in these group (Davis, 2003; Glasson et al., 2003; Schaumberg et al., 2002; Schaumberg et al., 2003; Toda et al., 2001).By: GlobalData, Published: Mar-2013, Product code: GDHCER011
PAGES:
37
TABLES:
6
FIGURES & CHARTS:
5
$3,995.00 -
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022 more info
GlobalData has released its new PharmaPoint Drug Evaluation report, “Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.By: GlobalData, Published: Mar-2013, Product code: GDHC1117DFR
PAGES:
49
TABLES:
11
FIGURES & CHARTS:
3
$3,495.00 -
EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 more info
Psoriasis is an immune-mediated chronic disorder of the skin characterized by redness and irritation. It affects people of both sexes and of all ages and races/ethnicities. The global prevalence of psoriasis varies geographically, with the disease being more prevalent in the colder areas of the north, and less prevalent in the tropics and warmer regions of the world (Weller et al., 2008). In European countries, psoriasis is more prevalent in residents of the colder central regions and less prevalent in residents of the southern regions. In some Asian countries, such as India, the prevalence of psoriasis is highest in the northern parts of the country. In contrast to India, China shows no difference in prevalence between the northern and southern regions (Bedi, 1995; Ding et al., 2012; Kawada et al., 2003; Naldi et al., 2004; Saraceno et al., 2006). In addition to the north-to-south prevalence gradient observed within most countries, the prevalence of psoriasis also varies among different countries. Globally, the prevalence of psoriasis varies from as low as 0.03% in Japan to as high as 3.15% in the US (Ding et al., 2012; Kawada et al., 2003). Differences in the reported prevalence between countries may be attributable to variations in environmental factors, genetic factors, and differences in the case definition used to diagnose psoriasis in epidemiology studies (Bedi, 1995; Ding et al., 2012; Gelfand et al., 2005b).By: GlobalData, Published: Mar-2013, Product code: GDHCER012
PAGES:
40
TABLES:
5
FIGURES & CHARTS:
4
$3,995.00 -
EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022 more info
Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the US and more than 35,000 cases in the European Union (EU) (Cystic Fibrosis Foundation Patient Registry, 2011; Farrell, 2008). CF causes abnormally thick, sticky mucus to accumulate in the respiratory, digestive, and reproductive systems. It is one of the most common chronic lung diseases and is widespread throughout the world. The specific defective gene that cases CF is the cystic fibrosis transmembrane conductance regulator (CFTR) gene.By: GlobalData, Published: Mar-2013, Product code: GDHCER015
PAGES:
35
TABLES:
5
FIGURES & CHARTS:
3
$3,995.00 -
EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022 more info
The urogenital tract, specifically the vagina, urethra, bladder, trigone of the bladder, and pelvic floor muscles, contains estrogen receptors. Estrogen is needed for the health of these tissues and structures, a lack of which causes them to undergo atrophy (Castelo-Branco and Rostro, 2007; Nappi and Kokot-Kierepa, 2012). During the menopause transition and postmenopausal periods, women can experience a number of symptoms primarily due to estrogen depletion that include vasomotor and urogenital symptoms. Although vasomotor symptoms typically resolve over time, urogenital symptoms remain a persistent consequence of estrogen depletion (Winneker and Harris, 2011). Postmenopausal vaginal atrophy (PVA) is the term used to describe the group of urogenital symptoms that arise due to estrogen depletion and is also known as urogenital atrophy, vulvovaginal atrophy, and atrophic vaginitis (Mac Bride et al., 2010; Willhite and O’Connell, 2001). Approximately 10%–50% of postmenopausal women experience symptoms of vaginal atrophy, but only about 25% of them seek medical treatment (NAMS, 2007; Nappi and Kokot-Kierepa, 2012).By: GlobalData, Published: Mar-2013, Product code: GDHCER021
PAGES:
30
TABLES:
5
FIGURES & CHARTS:
3
$3,995.00 -
Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022 more info
GlobalData has released its new PharmaPoint Drug Evaluation report, “Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.By: GlobalData, Published: Mar-2013, Product code: GDHC1122DFR
PAGES:
49
TABLES:
11
FIGURES & CHARTS:
3
$3,495.00
Refine Your Search
- Industry
- Price
- Publisher
- Region
- Report Type
Why buy direct from us?
Huge Selection
Industry Report Store has one of the largest databases of market research reports.
Instant Delivery
Most reports are available for immediate download upon purchase and full payment.
Best Price Guarantee
As we publish many of the reports ourselves, we set the prices and can offer special discounts.
All transactions are secured with SSL Security. 
Loading...